Abstract Number: 0238 • ACR Convergence 2024
Longitudinal Assessment of CD8+ T Cell Responses to SARS-CoV-2 Pre- and Post-breakthrough Infection and Its Association with COVID-19 Severity in Immunosuppressed Individuals
Background/Purpose: Vaccines for SARS-CoV-2 have greatly reduced COVID-19 morbidity and mortality through the induction of neutralizing antibody responses. However, T cell responses are also induced…Abstract Number: 1110 • ACR Convergence 2024
Microvascular Abnormalities in COVID-19 Survivors and LONG COVID
Background/Purpose: Coronavirus disease 2019 (COVID-19) is an infective disease known to cause mainly respiratory symptoms along with a wide range of systemic manifestations [1]. Long…Abstract Number: 2056 • ACR Convergence 2024
Deucravacitinib Treatment Did Not Impact Immune Response to SARS-CoV-2 Vaccines and Infection in Patients with Plaque Psoriasis: Results from the Phase 3 POETYK Long-Term Extension Trial
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…Abstract Number: 0239 • ACR Convergence 2024
Neutralising Antibody Responses to Bivalent SARS-CoV-2 Vaccines and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
Background/Purpose: The SARS-CoV-2 virus mutates continuously, posing challenges for patients with immune-mediated inflammatory diseases (IMIDs) on tumour necrosis factor inhibitors (TNFi). These patients often have…Abstract Number: 1146 • ACR Convergence 2024
Impact of COVID-19 on Myositis Testing Trends
Background/Purpose: Idiopathic inflammatory myopathies (IIM), also known as myositis, are a group of heterogeneous autoimmune disorders that lead to muscle injury. Autoantibodies help make the…Abstract Number: 2091 • ACR Convergence 2024
Changes in Analgesic Prescriptions for the Treatment of Osteoarthritis During the COVID-19 Pandemic
Background/Purpose: Osteoarthritis (OA) is a leading cause of disability. The 2019 American College of Rheumatology (ACR)/Arthritis Foundation (AF) Guideline for the Management of OA recommends…Abstract Number: 0240 • ACR Convergence 2024
Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated humoral vaccine responses and are prone to more severe infections. Assessing the persistence…Abstract Number: 1201 • ACR Convergence 2024
Association of COVID-19 Vaccinations with Osteoarthritis Flares: A Case-Crossover Study
Background/Purpose: People with osteoarthritis (OA) commonly experience periods of increased pain and stiffness (“flares”), which can be distressing and disabling. Despite the prevalence of OA…Abstract Number: 2182 • ACR Convergence 2024
PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results
Background/Purpose: The long-term sequelae of SARS-CoV-2 infection in children are unknown. PECOS is a large prospective observational cohort study with the main objective to characterize…Abstract Number: 0241 • ACR Convergence 2024
Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients
Background/Purpose: The ACR recommends SARS-CoV-2 vaccination for all patients with rheumatic diseases, but it is unknown how patients with SLE will respond to the vaccine,…Abstract Number: 1249 • ACR Convergence 2024
Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…Abstract Number: 2198 • ACR Convergence 2024
Severe and Long-Term Outcomes of COVID-19 Infection and Vaccine Hesitancy and Adverse Events in Children with Pediatric Rheumatic Diseases: Insights from a COVID-19 Global Rheumatology Alliance Caregiver Survey
Background/Purpose: Children have the lowest COVID-19 vaccination rates of any age group. In adults with rheumatic diseases, barriers to vaccination include the perceived lack of…Abstract Number: 0242 • ACR Convergence 2024
Use of Outpatient Antiviral Therapy and Severe Outcomes from SARS-CoV-2 Omicron Infection in Patients with Immune Mediated Diseases on B Cell Depleting Agents
Background/Purpose: Immunocompromised patients constitute a high-risk group for severe COVID-19 outcomes and those on B cell depleting therapy (BCTD) are among the most vulnerable. Previous…Abstract Number: 1531 • ACR Convergence 2024
Prospective mRNA SARS-CoV-2 Additional Vaccination in Systemic Autoimmune Disease Patients on Immunosuppressive Medications in a Randomized Controlled Trial
Background/Purpose: Autoimmune disease patients treated with mycophenolate mofetil/mycophenolic acid (MMF/MPA), methotrexate (MTX), or B cell-depleting therapies (BCDT) exhibit reduced humoral responses following primary two-dose COVID-19…Abstract Number: 2242 • ACR Convergence 2024
A Cross-sectional Study on Predictors of COVID-19 Infection, Admission and Mortality and Effect of Immunomodulating Treatments in Rheumatoid Arthritis
Background/Purpose: COVID-19 infection frequently leads to a cytokine storm, which has successfully been treated with some immunomodulating therapies according to observational studies. Interestingly, treatments investigated…
- 1
- 2
- 3
- …
- 38
- Next Page »